MannKind Reports Positive Phase 1b INFLO-1 IPF Results
Danbury, Conn. & Westlake Village, Calif., July 29, 2026 MannKind Corporation announced positive topline results from its Phase 1b...
respiratory disease
Advertisement
Revagenix Doses First Patient in Phase 1 Rev-56 Trial
SAN FRANCISCO, Calif., July 27, 2026 Revagenix, Inc. announced that the first participant has been dosed in the Phase...
Kinaset Doses First Patient in Phase 2b Frevecitinib Trial
BOSTON, MA, July 20, 2026 Kinaset Therapeutics announced that the first patient has been dosed in the Phase 2b...
Boehringer Ingelheim Wins EU Approval for JASCAYD
INGELHEIM, Germany, July 17, 2026 Boehringer Ingelheim has announced that the European Commission (EC) has granted marketing authorization for...
Sino Biopharm Secures $2.1B TQC3721 AstraZeneca Agreement
HONG KONG, July 8, 2026 Sino Biopharmaceutical Limited has announced that its subsidiary, Chia Tai Tianqing Pharmaceutical Group Co.,...
Advertisements
Kither Biotech Completes Phase 1 Trial of KIT2014
TURIN, Italy | June 19, 2026 Kither Biotech has announced the successful completion of its first-in-human Phase 1 clinical...
Boehringer Ingelheim Reports Survival Gains With Nerandomilast
INGELHEIM, Germany, June 18, 2026 Boehringer Ingelheim has announced new long-term survival modeling analyses from its pivotal Phase III...
Kelun-Biotech and Windward Bio Advance SKB378 in COPD
CHENGDU, China – June 9, 2026 Kelun-Biotech has announced that its partner Windward Bio has successfully dosed the first...
Altesa’s Vapendavir Shows Promise in Preventing COPD Flares
WASHINGTON, D.C., June 5, 2026 Altesa BioSciences has unveiled encouraging new Phase 2 clinical findings demonstrating that vapendavir, its...
ReCode Achieves First Clinical Success for Inhaled mRNA Therapy in PCD
MENLO PARK, California, May 20, 2026 ReCode Therapeutics announced positive clinical data from its RCT1100 inhaled mRNA therapy program...
Advertisement
